P. Poignard

发表

Highly Antigenically Diverse Viruses Broadly Neutralizing Antibodies Present New Prospects to Counter

D. Burton, I. Wilson, P. Poignard, 2012 .

Single-Virus Droplet Microfluidics for High-Throughput Screening of Neutralizing Epitopes on HIV Particles.

Christoph A. Merten, V. Beneš, P. Poignard, 2017, Cell chemical biology.

Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses.

Alessandro Sette, Mark M Davis, Mark M. Davis, 2013, Immunity.

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Ron Diskin, Beatrix Ueberheide, Michael S. Seaman, 2011, Science.

Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding

Dennis R. Burton, Pascal Poignard, D. Burton, 2014, Scientific Reports.

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Pham Phung, Terri Wrin, Dennis R. Burton, 2009, Science.

Broad neutralization coverage of HIV by multiple highly potent antibodies

Pham Phung, Terri Wrin, Chi-Huey Wong, 2011, Nature.

The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies

Daphne Koller, George M. Church, Jonathan Laserson, 2013, PLoS pathogens.

Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants

Pascal Poignard, Donald E. Mosier, Jill Wilken, 1999, Journal of Virology.

Profiling human antibody responses by integrated single-cell analysis.

Douglas S Kwon, J Christopher Love, Navin Varadarajan, 2014, Vaccine.

A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1

J. Binley, P. Poignard, M. Zwick, 2013, PloS one.

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

John P. Moore, D. Burton, B. Keele, 2011, Proceedings of the National Academy of Sciences.

Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies

F. Barin, M. Nussenzweig, A. Moreau, 2014, Journal of Virology.

Clinical and microbiological assessments of COVID-19 in healthcare 1 workers : a prospective longitudinal study 2

P. Poignard, K. Brengel-Pesce, M. Buisson, 2020 .

Stimulation of the primary anti‐HIV antibody response by IFN‐α in patients with acute HIV‐1 infection

C. Rouzioux, P. Poignard, P. Lebon, 2008, Journal of leukocyte biology.

Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes

Sergei L. Kosakovsky Pond, D. Burton, D. Montefiori, 2013, Journal of Virology.

Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque

D. Burton, I. Wilson, L. Walker, 2011, Proceedings of the National Academy of Sciences.

Human Immunodeﬁciency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identiﬁed by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm (cid:1) †

D. Burton, T. Wrin, E. Karita, 2009 .

Human and simian immunodeficiency viruses: virus-receptor interactions.

Q. Sattentau, P. Poignard, N. Signoret, 1993, Trends in microbiology.

Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use

J. Payen, P. Poignard, M. Buisson, 2021, Journal of Infection.

Fine Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Infected Patients: Differential Profiling of Patients With Severe Outcome

Marc C. Jacob, J. Cesbron, M. Roustit, 2022, Frontiers in immunology.

Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response

Sergei L. Kosakovsky Pond, D. Richman, S. Little, 2017, Journal of Virology.

Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding

Q. Sattentau, J. Moore, P. Poignard, 1993, Journal of virology.

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1

D. Ho, M. Nussenzweig, A. Moreau, 2016, Journal of acquired immune deficiency syndromes.

Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1

Christoph Grundner, Christos J. Petropoulos, Terri Wrin, 2003, Journal of Virology.

gp120: Biologic aspects of structural features.

D R Burton, D. Burton, P. Parren, 2001, Annual review of immunology.

Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient.

P. Poignard, B. Spire, C. Tamalet, 1998, Transplantation.

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

H. Katinger, D. Burton, P. Parren, 1999, Immunity.

Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study

J. Adnot, P. Poignard, K. Brengel-Pesce, 2021, Scientific Reports.

Clinical and microbiological assessments of COVID-19 in healthcare workers: a prospective longitudinal study

P. Poignard, K. Brengel-Pesce, M. Buisson, 2020, medRxiv.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage

Ben Murrell, Terri Wrin, Sergei L. Kosakovsky Pond, 2017, Immunity.

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort

Ben Murrell, Jianming Tang, Adam Godzik, 2016, PLoS pathogens.

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

Baoshan Zhang, Peter D. Kwong, Michael S. Seaman, 2015, Nature.

An MPER antibody neutralizes HIV-1 using germline features shared among donors

D. Burton, I. Wilson, A. Ward, 2019, Nature Communications.

Direct Antibody Access to the HIV-1 Membrane-Proximal External Region Positively Correlates with Neutralization Sensitivity

R. Wyatt, D. Burton, L. Walker, 2011, Journal of Virology.

Access of antibody molecules to th conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary HIV-1

J. Sodroski, J. Binley, R. Wyatt, 2009 .

Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies

D. Burton, P. Parren, P. Poignard, 2003, Journal of Virology.

Antibodies in human infectious disease

D. Burton, P. Parren, P. Poignard, 2000, Immunologic research.

Antibody neutralization of HIV-1 and the potential for vaccine design.

Q. Sattentau, P. Poignard, J. Guillemot, 1999, Immunology letters.

Antibody neutralization of HIV-1.

Q. Sattentau, P. Poignard, P. Klasse, 1996, Immunology today.

Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation

Q. Sattentau, J. Moore, P. Poignard, 1996, The Journal of experimental medicine.

Identification of peptides from human pathogens able to cross‐activate an HIV‐1‐gag‐specific CD4+ T cell clone

R. Simon, D. Burton, C. Pinilla, 2006, European journal of immunology.

Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Gag- and Gag Peptide-Specific CD4+ T-Cell Clones from an HIV-1-Seronegative Donor following In Vitro Immunization

D. Burton, P. Poignard, D. Mosier, 2002, Journal of Virology.

Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan

Ben Murrell, William R. Schief, Thomas Vollbrecht, 2019, Immunity.

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike

John P. Moore, D. Burton, I. Wilson, 2015, Nature Communications.

Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans

Ryan McBride, Robyn L. Stanfield, Andrew B. Ward, 2013, PLoS pathogens.

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Yan Liu, William R. Schief, Ryan McBride, 2011, Science.

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

Terri Wrin, Josephine Birungi, Dennis R. Burton, 2009, Journal of Virology.

Rapid Sequencing of Complete env Genes from Primary HIV-1 Samples.

Yan Guo, Ben Murrell, Pham Phung, 2016, Virus evolution.

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

D. Burton, H. Schuitemaker, T. Wrin, 2015, PLoS pathogens.

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

Lynn Morris, Yan Liu, Michael S. Seaman, 2012, The Journal of experimental medicine.

PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4

Tongqing Zhou, Terri Wrin, Peter D. Kwong, 2012, Journal of Virology.

Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

D. Burton, D. Watkins, W. Koff, 2009, Journal of Virology.

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

Pascal Poignard, Dennis R Burton, D. Burton, 2009, Nature Medicine.

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

D. Burton, D. Watkins, W. Koff, 2009, PLoS pathogens.

Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses

D. Burton, I. Wilson, P. Poignard, 2012, Science.

Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys

Michael S. Seaman, Florian Klein, Arup K. Chakraborty, 2013, Nature.

CXCL13 is a plasma biomarker of germinal center activity

Mark M. Davis, B. Walker, B. Pulendran, 2016, Proceedings of the National Academy of Sciences.

The Cambrian Conundrum: Early Divergence and Later Ecological Success in the Early History of Animals

John P. Moore, D. Burton, Chi‐Huey Wong, 2011 .

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Wayne C Koff, Chung-Yi Wu, Chi-Huey Wong, 2014, Immunity.

A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

S. Iida, D. Burton, P. Parren, 2012, Journal of Virology.

1 Monoclonal Antibody b 12 Has Enhanced Fc ? RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques Permalink

P. Parren, D. Watkins, J. Schmitz, 2012 .

Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies

J. Mascola, H. Katinger, D. Burton, 2003, Journal of Virology.

Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

James C Paulson, Pascal Poignard, Ian A Wilson, 2014, Immunity.

Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

Ben Murrell, Terri Wrin, Sergei L. Kosakovsky Pond, 2016, Immunity.

Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.

D. Burton, Chi‐Huey Wong, B. Briney, 2015, Immunity.

Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope

D. Burton, I. Wilson, Uri Laserson, 2014, Journal of Virology.

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

D. Burton, D. Watkins, P. Poignard, 2012, Proceedings of the National Academy of Sciences.

Correction: Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies

D. Burton, S. Kazer, A. Shalek, 2017, The Journal of experimental medicine.

Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies

D. Burton, S. Kazer, A. Shalek, 2017, The Journal of experimental medicine.

Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform

P. Poignard, G. Schoehn, M. Buisson, 2021, bioRxiv.

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

W. Weissenhorn, D. Guilligay, P. Poignard, 2021, bioRxiv.

Anti-HIV B Cell Lines as Candidate Vaccine Biosensors

J. Mascola, J. Binley, R. Wyatt, 2012, The Journal of Immunology.

A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

D. Burton, I. Wilson, Chi‐Huey Wong, 2016, Immunity.

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

J. Mascola, D. Burton, M. Nussenzweig, 2014, The Journal of experimental medicine.

A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals

Dennis R. Burton, Pascal Poignard, D. Burton, 2010, PLoS pathogens.

AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory Syndrome

J. Pépin, P. Poignard, M. Buisson, 2022, International journal of molecular sciences.

A Panel of IgG1 b12 Variants with Selectively Diminished or Enhanced Affinity for Fcγ Receptors To Define the Role of Effector Functions in Protection against HIV

D. Burton, J. Harvey, D. Dunlop, 2011, Journal of Virology.

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy

P. Poignard, S. Larrat, M. Le Maréchal, 2021, Emerging infectious diseases.

Human Antibody Responses to Mature and Immature Forms of Viral Envelope in Respiratory Syncytial Virus Infection: Significance for Subunit Vaccines

D. Burton, R. Chanock, J. Crowe, 1999, Journal of Virology.

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

D. Burton, I. Wilson, W. Koff, 2010, Proceedings of the National Academy of Sciences.

Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120

Paul W. H. I. Parren, Dennis R. Burton, Pascal Poignard, 2003, Journal of Virology.

Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design

I. Wilson, A. Ward, P. Poignard, 2018, Cell reports.

HIV: Immune memory downloaded

D. Burton, P. Poignard, 2009, Nature.

Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells.

T. Curiel, P. Poignard, E. Krug, 1993, Journal of immunology.

Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality

J. Cesbron, M. Roustit, P. Poignard, 2021, Frontiers in Immunology.

IDEPI: Rapid Prediction of HIV-1 Antibody Epitopes and Other Phenotypic Features from Sequence Data Using a Flexible Machine Learning Platform

Ben Murrell, Sergei L. Kosakovsky Pond, Konrad Scheffler, 2014, PLoS Comput. Biol..

Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies

H. Katinger, D. Burton, P. Parren, 2001, Journal of Virology.

Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV

D. Lauffenburger, F. Pereyra, B. Walker, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV

William R. Schief, Michael S. Seaman, Dennis R. Burton, 2014, Science Translational Medicine.

Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.

Q. Sattentau, S. Zolla-Pazner, P. Poignard, 1995, Virology.

Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies

D. Burton, B. Briney, Collin Joyce, 2023, PLoS pathogens.

A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition

W. Weissenhorn, R. Weiss, J. Simorre, 2013, PLoS pathogens.

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.

Q. Sattentau, D. Burton, P. Parren, 1997, Immunology letters.

Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies

D. Burton, T. Wrin, P. Poignard, 2016, Retrovirology.

Neutralizing Antibodies Afforded by Passive Infusion of Does Not Augment the Sterile Protection Immunodeficiency Virus DNA Vaccination Immunodeficiency Virus Type 1 / Simian Cellular Immunity Elicited by Human

J. Mascola, H. Katinger, D. Burton, 2003 .

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

Q. Sattentau, D. Burton, P. Parren, 1997, Immunology letters.

Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2

D. Burton, D. Watkins, Noëlie Campos, 2012, PloS one.

Correction: Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies

D. Burton, S. Kazer, A. Shalek, 2017, The Journal of experimental medicine.

Fine analysis of lymphocyte subpopulations in SARS-CoV-2 infected patients: toward a differential profiling of patients with severe outcome

Marc C. Jacob, J. Cesbron, M. Roustit, 2021, medRxiv.

Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.

D. Burton, Chi‐Huey Wong, P. Poignard, 2015, Immunity.

Erwin Success in the Early History of Animals The Cambrian Conundrum : Early Divergence and Later Ecological

John P. Moore, D. Burton, Chi‐Huey Wong, 2011 .

FUBAR: A Fast, Unconstrained Bayesian AppRoximation for Inferring Selection

D. Richman, D. Burton, P. Poignard, 2014 .